Allogene Therapeutics Inc. (ALLO) Fundamentals

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
SHARE INFORMATION
Market Cap$ 1,091,362,386
Shares Outstanding143,600,314
Float89,608,119
Percent Float62.4%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 38,489,000
Latest Fiscal EPS$ -1.89
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions447
Institutional Holdings Date2022-04-30
Institutional Bought Previous 3 Months12,024,292
Institutional Holdings Percent108.5%
Institutional Sold Previous 3 Months25,600,213
Insider Holdings Date2022-03-31
Insider Bought Previous 3 Months11,343,569
Insider Holdings Percent3.4
Insider Sold Previous 3 Months5,180,572
Insider Shares Owned4,913,795
TRADING INFO
52 Week High$ 31.77
52 Week Low$ 6.43
52 Week High Change$ -73.43
21 Day Moving Average$ 8.0929
21 Day Extended Moving Average$ 8.0315
50 Day Moving Average$ 8.6252
50 Day Extended Moving Average$ 8.7762
200 Day Moving Average$ 15.2693
200 Day Extended Moving Average$ 14.6314
10 Day Average Volume2,454,985
20 Day Average Volume2,307,199
30 Day Average Volume1,961,260
50 Day Average Volume1,899,883
Alpha-0.017738
Beta0.8754
Standard Deviation0.198183
R20.056068
7 Day Price Change$ -0.07
7 Day Percent Change-0.91%
21 Day Price Change$ -0.86
21 Day Percent Change-10.17%
30 Day Price Change$ -0.65
30 Day Percent Change-7.88%
Month to Date Price Change$ -0.75
Month to Date Percent Change-8.98%
Quarter to Date Price Change$ -1.51
Quarter to Date Percent Change-16.58%
180 Day Price Change$ -11.42
180 Day Percent Change-60.04%
200 Day Price Change$ -9.64
200 Day Percent Change-55.92%
Year to Date Price Change$ -7.32
Year to Date Percent Change-49.06%

Allogene Therapeutics Inc. (ALLO) Key Ratios

PROFITABILITY
EBIT Margin-147,601.5%
EBITDA Margin-141,636.6%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 205,000
Revenue Per Share$ 0.0014
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book1.20
Total Debt To Equity0.10
Int Coverage0.00
Current Ratio12.70
Leverage Ratio1.10
Quick Ratio12.20
Long Term Debt To Capital0.07
VALUATION MEASURES
PE Ratio-3.20
Enterprise Value$ 636,675,223
Price to Sales5,323.719
Price to Free Cash-4.60
PE High Last 5 Years0.00
Price To Book1.20
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book1.20
MANAGEMENT EFFECTIVENESS
Receivables Turnover32.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-28.35
Return on Equity-31.57
Return on Capital-29.87

Allogene Therapeutics Inc. (ALLO) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorErnst & Young LLP
CEODavid D. Chang
Emplyoees334
Last AuditUQ
CIK0001737287
IndustryBiotechnology
SectorHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing(325414)
CONTACT INFO
Address210 East Grand Avenue
South San Francisco, CA 94080
Websitehttps://www.allogene.com
Facsimile-
Telephone+1 650 457-2700
EmailChristine.Cassiano@allogene.com


Your Recent History
NASDAQ
ALLO
Allogene T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.